15 results about "Biomarker Analysis" patented technology

We provide specimen analyzers, specimen analysis systems, specimen analysis methods, and programs that can contribute to highly accurate dementia diagnosis using dementia biomarkers. [Solution] The specimen analyzer 1 comprises a measuring device 2 that measures analytes related to dementia biomarkers contained in a specimen taken from a subject, a storage unit that stores reference values ​​for identifying outliers that may occur due to factors other than dementia, a control unit that determines whether the measured value is identified as an outlier based on the measured value of the analyte by the measuring device 2 and the reference value, and generates biomarker analysis results according to the result of the determination, and an output unit that outputs the biomarker analysis results.

A wearable smart ring includes an annular body sized to receive a finger, photoplethysmography (PPG) sensors arranged along an inner peripheral surface, and a microfluidic perspiration collector disposed at the inner surface. The collector has microchannels that draw perspiration by capillary action into one or more reservoirs and includes a region that concentrates or retains biomarkers. A docking station mechanically receives the ring for charging and interfaces with the collector to transfer fluid and / or perform in-situ analysis. The dock includes optical instrumentation (e.g., photometry, spectroscopy such as Raman) and may implement pumping and flushing to reset the collector for subsequent use. A controller communicates results by wireless links. The system enables passive collection of perspiration during wear and detailed biomarker analysis during charging, thereby augmenting PPG-derived physiological measurements with perspiration chemistry without burdening ring power or size.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

Disclosed are novel RNA and protein expression panels and methods of using said panels for the detection of cancer and determining the suitability of a subject for a treatment regimen or clinical trial.

The invention discloses a carrier for acquiring life information and a method for applying the carrier, and belongs to the technical field of biomedicine. The method solves the problem that a required sample is difficult to quickly obtain during practical application of an existing method, realizes accurate extraction and detection of a life information carrier by integrating a magnetic bead separation technology and fluorescent quantitative detection, and performs intelligent classified storage and dynamic management based on data volume and data type, so that the life information carrier can be accurately extracted and detected during practical application. According to the method, quick retrieval and application can be performed in the specified storage area according to the data volume of the life information required to be applied, so that the management efficiency and retrieval speed of the life information are remarkably improved; the system can realize rapid biomarker analysis in disease diagnosis, supports dynamic data tracking in treatment monitoring, promotes accurate scheme formulation in personalized medical treatment, and achieves the comprehensive effects of improving medical detection efficiency, reducing storage cost and enhancing clinical application flexibility.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

Systems, devices, and methods for skin biomarker analysis and computation of predicted responsiveness to skincare treatments for management of skin health. A system is configured to receive a measurement of one or more skin biomarkers, compute a predicted beauty outcome that is predicted to occur due to a course of action, and recommend or not recommend the course of action, based on the responsiveness metric, such that the skin health of the individual is advanced toward a desired beauty outcome. Systems can recommend products, services, and other courses of action such as lifestyle changes, to improve the health of the individual.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

This disclosure relates generally to the use of automated platforms in the preparation of biomarker-stained cellular samples for microscopic analysis and use of such stained cells in the diagnosis of certain conditions. Disclosed herein is a method of affinity staining a Romanowsky-type stained sample on automated advanced staining systems, wherein the automated advanced stainer destains the sample prior to contact with a biomarker-specific reagent. Also disclosed herein are methods of processing body fluid samples for morphological and biomarker analysis by depositing cells of the sample in a thin layer onto one or more solid supports, staining at least one such solid support with a Romanowsky-type stain and staining at least one such solid support for one or more biomarkers useful for categorizing one or more cells of the sample.

Provided herein are devices, systems, kits and methods for predicting or determining the gender of a fetus using cell free fetal nucleic acids in a small amount of maternal biological sample. Devices can be used at point of need during early stages of pregnancy and are compatible with communication devices.

The field of this invention relates to immunohistochemistry (IHC), immunocytochemistry and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins, glycans and RNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to Probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry, immunocytochemistry and in situ hybridization, with mass spectrometry (MS) and mass spectrometry imaging (MSI) as the mode of detection / readout.

This application provides a system, method, media, program product, and terminal for vascular biomarker analysis and disease diagnosis based on ultrasound-guided microscopy. This application utilizes a unified and optimized ULM (Ultra-Large-Scale Microscopy) workflow to reconstruct complex vascular networks with high precision and resolution. It enables longitudinal imaging of the same observation area, accurately quantifying multidimensional biomarkers and monitoring their changes over time, making it suitable for monitoring disease progression or treatment response. By identifying disease-specific multidimensional biomarkers, this application has successfully differentiated between benign and malignant diseases in clinical trials. This application can be seamlessly integrated into existing clinical ultrasound equipment workflows, enabling microvascular imaging, biomarker extraction, and analysis. The standardized operating procedures and automated analysis significantly lower the technical barrier to entry, assisting scientists and physicians in disease diagnosis and possessing direct potential for clinical application.

The invention belongs to the field of medical detection, and discloses a nucleic acid aptamer for recognizing sarcosine and application of the nucleic acid aptamer. The aptamer is obtained by constructing an ssDNA initial library containing fixed primers at the two ends and 36 random basic groups in the middle, repeated incubation and screening are conducted through positive screening magnetic beads and negative screening magnetic beads, the positive screening magnetic beads are formed by coupling carboxyl functionalized magnetic beads with sarcosine, and the negative screening magnetic beads are formed by coupling carboxyl functionalized magnetic beads with glycine and alanine. Based on the nucleic acid aptamer, the invention also provides a nucleic acid aptamer-magnetic bead chemiluminescence kit, the kit comprises a reagent 1 and a reagent 2, the reagent 1 comprises a streptavidin magnetic bead coupled nucleic acid aptamer, and the reagent 2 comprises an acridinium ester labeled nucleic acid aptamer. The nucleic acid aptamer is high in stability and specificity, the detection method is easy and convenient to operate, the cost is low, detection is rapid, the nucleic acid aptamer is suitable for efficient detection of sarcosine in complex biological samples, and the nucleic acid aptamer has important application value in the fields of disease diagnosis and biomarker analysis.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection / readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).